
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
GlobalData's latest report says the Chronic Obstructive Pulmonary Disease pipeline is lagging in terms of first-in-class product innovation when it comes to asthma.
Read more about it







